Emergent BioSolutions Inc.
Customers 1
Companies EBS discloses as major customers, as a share of EBS revenue. 1 active, 0 lapsed.
| Company | % of EBS revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| United States Government Non-SEC United States Government |
46% | $341.7M | FY 2025-12-31 | +7.0pp | Active | 10-K 2026-02-27 |
Billed accounts receivable are stated at invoice amounts and consist of amounts due from the United States Government ("USG"), commercial and Bioservices customers, as well as amounts due under reimbursement contracts with other government entities and non-government organizations. | ||||||
Suppliers 1
Companies that disclose EBS as a major customer, as a share of their own revenue. 1 active, 0 lapsed.
| Company | % of their revenue | Est. $ from EBS | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| MGNX MACROGENICS INC |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-09 |
Emergent Biosolutions 16 % * | ||||||
Federal contracts 2
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $218.8M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response |
$197.3M | FY 2026 | 10 | $394.0M → $437.3M → $282.8M → $197.3M | 75A50119C00075 |
BOTULISM ANTITOXIN | |||||
| Department of Defense
Department of the Army |
$21.5M | FY 2026 | 2 | $19.9M → $20.8M → $21.5M | W911SR26FA005 |
FOR THE PROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ABSORBED (AVA)) | |||||
Federal subcontracts received 1
Prime contractors that subcontracted federal work to this company. From USAspending.gov subaward reports; amounts are as reported by the prime contractor, latest report per subaward, $500K+ a year.
| Company | Subawards | Fiscal year | Count | Trend | Largest subaward |
|---|---|---|---|---|---|
| Canadian Commercial Corporation | $767.1K | FY 2025 | 8 | SPE2D625F5Z2G | |
REACTIVE SKIN DECONTAMINATION LOTION | |||||
Unnamed major customers
Disclosed without names in the fiscal year ending 2022-12-31. Identities are not inferred.
Alerts are coming
Get an email when EBS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.